Aspen’s response to the reported Competition Commission investigation ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number 1985/0002935/06 Share code: APN ISIN: ZAE000066692 and its subsidiaries (collectively “Aspen” or “the Aspen Group”) ASPEN’S RESPONSE TO THE REPORTED COMPETITION COMMISSION INVESTIGATION Media reports that the Competition Commission has decided to take up the Democratic Alliance’s request to investigate the alleged anti-competitive conduct of Aspen in South Africa, in its preliminary investigation into the pharmaceutical sector, has reference. Aspen welcomes the process and the opportunity to categorically set aside such allegations of anti- competitive behavior. Aspen is committed to full and constructive engagement with the Competition Commission should it wish to pursue such an investigation. It is worth noting that pharmaceutical prices are approved by the Department of Health in terms of the Single Exit Price regulatory framework which establishes a universal fixed price for each pharmaceutical product. Aspen has not increased pricing of its products outside of this regulatory framework. Durban 24 April 2017 Sponsor: Investec Bank Limited Date: 24/04/2017 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.